CUSTOMER SERVICE  |  814.355.1030  |  Toll Free: 800.342.3595  |  M-F: 8am-4pm EST/EDT

Anti-ganglioside asialo GM2 (polyclonal antibody)

CATALOG # 1951


  • Catalog #:1951
  • Scientific Name:Anti-ganglioside asialo GM2 (polyclonal antibody)
  • Common Name:Polyclonal antibody to asialo GM2, isotype IgG/IgM
  • SDS:View Safety Data Sheet
  • Data Sheet:View Data Sheet
  • Unit:50 µl
  • Solvent:none
  • Source:rabbit
  • Purity:serum, not purified
  • Analytical Methods:ELISA, TLC immunoblotting
  • Natural Source:rabbit
  • Solubility:water
  • Physical Appearance:liquid
  • Storage:-20°C
  • Dry Ice:Yes
  • Hazardous:Yes


Application Notes:

Anti-ganglioside asialo GM2 is very useful in the identification of ganglioside asialo GM2 and in immunotargeting cells expressing asialo GM2. Several gangliosides have been found to have an elevated expression in tumor cells. Many therapeutic treatments of tumor cells are being investigated using antibodies to target cells that express these elevated levels of gangliosides. Lymphoma has been shown to have an increased level of asialo GM2 and passive immunization with monoclonal immunoglobulin G3 antibodies to asialo GM2 has effectively suppressed tumor formation in these cells.3 Asialo- GM2 has been identified as a receptor for many types of bacteria including Neisseria gonorrhoeae and Haemophilus influenzae.

1. H. Yoshino et al. “Fucosyl-GM1 in Human Sensory Nervous Tissue Is a Target Antigen in Patients with Autoimmune Neuropathies” Journal of Neurochemistty, Vol. 61 pp. 658, 1993
2. S. Kusunoki et al. “Neuropathy and IgM paraproteinemia: Differential binding of IgM M-proteins to peripheral nerve glycolipids” Neurology, Vol. 37 pp. 1795, 1987
3. W. Young Jr and S. Hakomori “Therapy of mouse lymphoma with monoclonal antibodies to glycolipid: selection of low antigenic variants in vivo” Science, Vol. 211:4481 pp. 487-489, 1981
Price $446.00

Others Also Bought

Catalog #:
Catalog #:
Catalog #: 1504
CAS#: 62010-37-1
Unit: 5 mg

Customer Reviews

Average Rating
Sign up for news & updates! Sign up!
Please Wait... processing